Searched for
INVESTING IN ANTHEM BIOSCIENCES
Quant Mid Cap Fund adds Adani Energy and 4 others, exits Paytm and 3 more stocks in MayQuant Mid Cap Fund, managed by Sandeep Tandon, has strategically adjusted its portfolio in May. The fund added Adani Energy and four other ...- Time to buy? Sunny Agrawal finds best picks across banking, pharma, capital markets & infrastructureIndian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...
- Ahead of Market: 10 things that will decide stock market action on TuesdayNifty 50 and Sensex fell sharply, dragged by banks, auto, and consumer stocks amid Iran-Israel tensions, high crude prices, and rupee lows,...
- Quant Mid Cap Fund makes complete exit from IRCTC and increases stake in Anthem Biosciences and 4 otherQuant Mid Cap Fund exited IRCTC in December, sold GMR Airports shares, and added stakes in Anthem Biosciences, PB Fintech, SBI Cards, Premi...
- Nomura initiates coverage on this recently-listed CRDMO stock, sees 18% upside despite 22% correctionNomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positio...
- Quant Mid Cap Fund reduces stake in RIL, raises exposure in OFSS in October. Check exits & additionsQuant Mid Cap Fund adjusted its holdings in October. The fund reduced its stake in Reliance Industries. It also increased its investment in...
- Mutual funds allocate Rs 8,752 crore to IPOs, continue backing small-cap growth stories: VenturaMutual funds invested over Rs 8,752 crore in recent IPOs during the September 2025 quarter, primarily in small-cap companies. Equity scheme...
- Quant Mid Cap Fund exits Bharat Forge & 2 others, trims exposure in Ajanta Pharma in AugustQuant Mid Cap Fund exited Bharat Forge, Colgate-Palmolive (India), and Aditya Birla Fashion and Retail in August, while reducing its stake ...
- AMFI reshuffle: Swiggy, Dixon Tech likely to move to largecap; HDB Financial may join midcap segmentSwiggy and Dixon Technologies may be upgraded to large-cap, while HDB Financial Services could enter the midcap segment in AMFI’s February ...
- Quant Small Cap Fund hikes stake in Jio Financial Services in JulyQuant Small Cap Fund raised its stake in Jio Financial Services in July, adding nearly 45 lakh shares. The fund also increased exposure to ...
- Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?Anthem Biosciences share price: Anthem’s IPO did not include a fresh issue, with all proceeds going to existing shareholders. Prior to the ...
- Anthem Biosciences IPO subscribed 2x on day 2; Check GMP, and other key detailsAnthem Biosciences' IPO witnessed strong investor interest, being oversubscribed 2.08 times on Day 2, driven by NIIs. Brokerages recommend ...
- Is Anthem Biosciences IPO a risky bet for investors?Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit h...
- India's IPO market loses steam on global market jittersSeveral Indian companies are delaying their initial public offerings. This is due to weak investor sentiment and global economic uncertaint...
- BlueStone Jewellery, Anthem Biosciences, Aye Finance and GK Energy get Sebi nod to launch IPO, to collectively raise over Rs 6,300 croreBlueStone Jewellery, Anthem Biosciences, Aye Finance, and GK Energy have received SEBI's approval for their IPOs. BlueStone aims to raise ₹...
- Private equity fund True North acquires minority stake in Bengaluru-based Anthem BioSet up by ex-Biocon executive Ajay Bharadwaj, Rs.1200-crore Anthem Biosciences competes with Biocon owned Syngene International and Hyderab...
- Multiples PE looks to exit Encube Ethicals at a valuation of $800 millionEncube Ethicals' promoter Mehul Shah will also sell about 5-10% stake in the company. A clutch of private equity funds, including Carlyle, ...
- Global PE funds eye stake in GVK Bio, co valued at $800 mnIn this proposed transaction, GVK BIO- promoted by the GVK Group and DS Brar, the former CEO and managing director of Ranbaxy Laboratories,...
- Anthem Bio catches global buyout funds' eye, stake sale could see valuation rocket to $1 billionLaunched by ex-Biocon executive Ajay Bharadwaj, the Rs 1,200 crore Anthem Biosciences competes with Syngene International and GVK Bio. O3 C...
- C-CAMP launches fourth edition of bio-entrepreneurship competitionNBEC, India’s largest and most prestigious national competition for bio entrepreneurs is held by C-CAMP every year to attract, identify and...
Load More
